Multimodal analysis of cell-free DNA identifies epigenetic biomarkers for amyotrophic lateral sclerosis diagnosis and progression
Liquid biopsy detects ALS from a blood draw with 91% accuracy—far faster than the current 12+ month diagnostic odyssey—and tracks disease progression.
A liquid biopsy approach using cell-free DNA methylation analysis achieves AUC 0.91 for ALS diagnosis with 70% sensitivity at near-perfect specificity — far exceeding existing diagnostic biomarkers for a disease that currently requires 12+ months to diagnose clinically. Methylation signatures also correlate with disease progression markers (CSF neurofilament), suggesting potential as a monitoring tool for clinical trial stratification.
What the study was
- Study design
- Case-control discovery and validation study
- Population
- ALS patients (sporadic and C9orf72-associated), asymptomatic carriers, and healthy controls
- Sample size
- 61
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Journal of Clinical Investigation
Why it surfaced
cfDNA liquid biopsy applied to ALS — a disease with no validated blood-based diagnostic biomarker and notoriously delayed diagnosis — achieves AUC 0.91, a remarkable performance; JCI is one of the highest-impact clinical research journals; epigenetic cfDNA methodology is on the watchlist; small n=61 limits immediate clinical translation but the signal strength (100% specificity) is exceptional. Applies cfDNA watchlist topic to neurological disease rather than cancer specifically.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.